ClinicalTrials.gg
RecruitingNCT07348471FMTIDUpdated Apr 3, 2026

Fecal Microbiota Transplantation for the Treatment of ICU Delirium

An interventional study of Intestinal microbiota suspension in Delirium, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Delirium with a site in China — 29 open to participants now, 30 under way, none of them phase 3. Delirium · China.

Planned enrollment
59th of 66
60 · median 262
Started
2026
with 5 others
No phase
40 of 96
13 open now
Primary completion
2028-12
later than 27 of 29 live
Registered
90th of 96
by date

Among the 96 studies in Delirium with a site in China, this one is the 59th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2026, is one of 40 with no phase, reaches primary completion later than 27 of the 29 other live ones, and was the 90th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

29 of the 96 studies in Delirium with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Delirium with a site in China, or all of them as a file.
02

Study summary

Delirium in the intensive care unit (ICU) is a prevalent and serious neurological complication among critically ill patients, with large multicenter studies reporting an incidence of 30% to 80%, particularly in those requiring mechanical ventilation. Delirium is not only associated with prolonged ICU and hospital stays but also with increased morbidity and mortality. Notably, up to 40% of survivors suffer from persistent cognitive dysfunction that may last for months or even years. Despite current standard pharmacological interventions-such as haloperidol and second-generation antipsychotics-failing to demonstrate significant clinical benefit in phase III trials, non-pharmacological strategies remain challenging to implement due to environmental and operational constraints within the ICU. This unmet clinical need underscores the imperative to develop novel, effective therapeutic approaches.

Emerging evidence suggests that ICU-acquired gut microbiota dysbiosis plays a pivotal role in the pathogenesis of delirium. Dysbiosis can compromise intestinal barrier integrity, promoting systemic inflammation and increasing susceptibility to various forms of delirium, including acute illness-related and postoperative types. These effects are likely mediated through the "gut-microbiota-brain axis," which may represent a central mechanism underlying neurocognitive dysfunction in critical illness.

Preclinical studies have demonstrated that fecal microbiota transplantation (FMT) can restore microbial balance and exert beneficial effects on neurological function. FMT has shown promise in ameliorating cognitive deficits in models of Alzheimer's disease, chronic cerebral hypoperfusion, traumatic brain injury, and chronic unpredictable mild stress (CUMS). Clinically, FMT has been associated with cognitive improvement in patients with dementia, recurrent Clostridioides difficile infection, and sepsis-associated encephalopathy. With expanding applications in both gastrointestinal and extraintestinal disorders, FMT has emerged as a transformative therapeutic modality, supported by robust short- and long-term safety and efficacy data.

This study aims to evaluate whether FMT can alleviate delirium severity, correct gut microbiota dysbiosis at 0, 72, and 120 hours post-enrollment, attenuate intestinal barrier dysfunction, reduce systemic inflammation and disease severity, shorten ICU length of stay, and lower rates of ICU mortality, in-hospital mortality, and 28-day all-cause mortality-ultimately positioning FMT as a potential breakthrough intervention for ICU delirium.

03

Conditions studied

  • Delirium

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age ≥ 18 years old, no ethnic or gender restrictions;
  • 2. CAM-ICU-positive delirium;
  • 3. Expected ICU stay ≥ 5 days after inclusion in the study;
  • 4. Signed written .

Exclusion criteria

Exclusion Criteria:

  • 1. Routine administration of antipsychotic medications: Conventional antipsychotic therapy refers to the daily ingestion or application of any sustained-release formulation (in any dosage form) of antipsychotic drugs with the ATC code N05A (in any form), including the following agents:

    1. Typical antipsychotics: Chlorprothixene, Flupentixol, Haloperidol, Levomepromazine, Loxapine, Melperone, Perphenazine, Pericyazine, Pimozide, Prochlorperazine, Zuclopenthixol, Pimavanserin, Sulpiride.
    2. Atypical antipsychotics: Amisulpride, Aripiprazole, Asenapine, Clozapine, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Sertindole, Ziprasidone. However, the non-habitual administration of antipsychotic medications in the general ward prior to the patient's ICU admission (e.g., for the management of delirium) is deemed acceptable. Nevertheless, antipsychotic therapy should be discontinued upon the patient's ICU admission.
  • 2. Severe systemic infection in the early stage of resuscitation, hemodynamic instability or insufficient tissue perfusion, and severe imbalance of water, electrolyte and acid-base.
  • 3. Patients with a high risk of death within 5 days as judged by the clinician, or those whose treatment decisions are restricted.
  • 4. Active major gastrointestinal bleeding, perforation, or other severe damage to the intestinal barrier.
  • 5. Patients who cannot tolerate 50% of their caloric requirements through enteral nutrition due to severe diarrhea, significant fibrotic intestinal stenosis, severe gastrointestinal bleeding, or high-flow enteric fistula.
  • 6. Planned or recent abdominal surgery (within 14 days).
  • 7. Currently diagnosed with fulminant colitis or toxic megacolon.
  • 8. Recently received high-risk or cytotoxic drug treatment: such as rituximab, doxorubicin, or medium to high-dose (20 mg/d prednisone or higher) for more than 4 weeks.
  • 9. Pregnant or lactating women.
  • 10. Participated in other clinical trials as a subject within the past 3 months or at the time of enrollment.
  • 11. Delirium assessment non applicable: this includes language barriers (patients with foreign language where delirium assessment cannot be confidently performed by the site staff), patients who are deaf, blind or aphasic. Comatose patients are not applicable for delirium assessment. Coma is defined by the following levels of consciousness: RASS -4 to -5. Further, RASS -3 may be considered as coma if this is the judgement of the treating physician. If a patient's coma is considered related to administration of sedative agents, an effort should be made to reduce or terminate the sedative treatment, according to the clinician's discretion.
  • 12. Doubtful validity of : subjects with mental illness, intellectual disability, poor motivation, or other factors that limit the validity of informed consent for participation in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    Control group

    The control group received standard ICU care, which includes monitoring vital signs, managing underlying conditions, infection treatment, nutritional support, and sedation or analgesia as per established clinical guidelines. These patients did not receive fecal microbiota transplantation (FMT). Treatment decisions were made by the attending physician according to standard ICU protocols and routine clinical practice.

  • Experimental
    FMT intervention Group

    FMT was administered via nasojejunal tube in addition to standard ICU care. A volume of 50-100 mL of intestinal microbiota suspension was delivered daily through the nasojejunal tube over a three-day period, between 11:00 and 13:00 each day.

    Other: Intestinal microbiota suspension

Interventions

  • OtherIntestinal microbiota suspension

    FMT was administered via a nasojejunal tube daily for three consecutive days, between 11:00 and 13:00. Each 50-100 mL dose, derived from 100-150 g of adolescent donor feces diluted to 300 mL. Patients fasted for 2 hours before and after FMT, except for permitted water intake. Intravenous antibiotics were withheld unless active infection was confirmed. If pathogens were considered colonizing and the patient remained stable, systemic antibiotics were avoided. Localized treatments, such as nebulized antibiotics, were allowed as needed. All antibiotic use required clinical justification and individual assessment to minimize interference with FMT. Oral antibiotics were prohibited after FMT initiation to protect engraftment and microbial integrity.

06

What researchers measure

Primary outcomes

  1. Delirium-free days (DFDs)

    The CAM-ICU is a standardized tool specifically designed for the rapid screening of delirium in ICU patients. It achieves efficient diagnosis by evaluating indicators including consciousness state, attention, and disordered thinking. and perceptual abnormalities. Delirium can be diagnosed if features 1 and 2 are met, and at least 3 or 4 are present. The assessment process is standardized, and medical staff can operate independently after training. For patients who survived and were discharged from the ICU or hospital during the study observation period, the entire period subsequent to their discharge date shall be counted as delirium-free. For patients who died during the study observation period, the interval from their date of death to the end of the observation period shall be recorded as 0 delirium-free days. DFDs = Total observation days - Days with delirium - Days with coma - Days from death to the end of observation.

    Time frame: During the first 28 days post-enrollment

Secondary outcomes

  1. CAM-ICU-7 score

    A 7-point rating scale (0-7) was derived from the CAM-ICU and RASS assessments. The final CAM-ICU-7 score ranges from 0-7 with 7 being most severe. CAM-ICU-7 scores were further categorized as 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.

    Time frame: From ICU admission to ICU discharge or death during ICU stay.

  2. Changes in intestinal microbiota composition

    Metagenomic profiling of fecal samples obtained via rectal swabs to assess: Changes in alpha-diversity (Shannon index), beta-diversity (Bray-Curtis dissimilarity), and relative abundance of specific bacterial taxa.

    Time frame: At 0, 72, and 120 hours post-inclusion

  3. Alterations in serum metabolites

    Serum samples were collected for non-targeted metabolomics analysis to comprehensively examine the composition and changes of endogenous small molecule metabolites in the blood.

    Time frame: At 0, 72, and 120 hours post-inclusion

  4. Acute Gastrointestinal Injury (AGI) Score

    The AGI scoring system is a standardized tool in critical care for assessing gastrointestinal dysfunction severity. It divides injury into four grades based on clinical and physiological findings: Grade I involves partial gastrointestinal impairment, such as feeding intolerance or transient diarrhea; Grade II includes gastrointestinal dysfunction, like gastroparesis with aspiration risk or abdominal compartment syndrome; Grade III indicates gastrointestinal failure, marked by persistent feeding intolerance or intestinal ischemia; Grade IV features gastrointestinal failure with severe systemic consequences, including intestinal necrosis or septic shock. This system supports dynamic assessment and guides clinical intervention in critically ill patients.

    Time frame: At 0, 24, 48, 72, 96, and 120 hours post-inclusion

  5. APACHE ⅡScore

    The APACHE II scoring system includes three components: the Acute Physiology Score (APS), Age Score, and Chronic Health Evaluation. The total score, ranging from 0 to 71, reflects disease severity, with higher values indicating worse condition. The APS incorporates 12 physiological variables. A built-in formula calculates individual risk of death (R); averaging all R values gives the predicted mortality rate for a patient group. APACHE II is a key tool for assessing critically ill patients in ICU.

    Time frame: At 0, 24, 48, 72, 96, and 120 hours post-inclusion

  6. Length of stay in the ICU

    Duration of ICU stay, defined as the number of days from patient admission to the intensive care unit until either discharge from the ICU or in-ICU mortality.

    Time frame: Up to 4 weeks after inclusion

  7. ICU mortality rate

    The ICU mortality rate is defined as the proportion of patients admitted to the ICU who die during their ICU stay, calculated as the number of deaths occurring within the ICU divided by the total number of ICU admissions, excluding patients transferred to other facilities or discharged against medical advice.

    Time frame: Up to 4 weeks after inclusion

  8. In-hospital mortality rate

    The in-hospital mortality rate is a standardized clinical outcome measure defined as the proportion of patients admitted to the hospital who die during their stay, calculated as the number of deaths occurring from admission to death.

    Time frame: Up to 4 weeks after inclusion

  9. Number of days alive and discharged within 28 days

    "Number of days alive and discharged within 28 days" is defined as the total number of days that a patient remains both alive and in a discharged state within the 28-day period starting from the date of the first FMT administration.

    Time frame: Up to 28 days after inclusion

  10. Number of days survived without mechanical ventilation within 28 days

    "Number of days survived without mechanical ventilation within 28 days" is defined as the total number of days during the 28-day period following the first administration of FMT on which the patient remains both alive and not requiring invasive or non-invasive mechanical ventilation.

    Time frame: Up to 28 days after inclusion

  11. 28-day all-cause mortality rate

    The 28-day all-cause mortality rate refers to the proportion of individuals who die from any cause within 28 days following a specific event or admission, and is commonly used as a standardized outcome measure in clinical studies.

    Time frame: Up to 28 days after inclusion

07

Study locations

1 of 1 sites recruiting
  • Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

Of 219 non-industry interventional studies with no phase under Delirium, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 33 months is above that.

Counting every sponsor, half of 222 studies reached it within 26 months; a quarter within 12 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Jan 16, 2026
StartActual
Mar 18, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07348471
Responsible party
Jiancheng Zhang (Prof. Jiancheng Zhang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Jan 16, 2026
Start date
Mar 18, 2026
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Apr 3, 2026

Study contacts

Jiancheng Zhang
Contact
zhjcheng1@126.com
8613554105815

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion